Drugs /

ibrutinib

Back to Drugs List
Associated Genetic Biomarkers
Associated Diseases

Overview

Generic Name(s):
ibrutinib
Trade Name(s):
Imbruvica
NCI Definition [1]:
An orally bioavailable, small-molecule inhibitor of Bruton's tyrosine kinase (BTK) with potential antineoplastic activity. Upon oral administration, ibrutinib binds to and irreversibly inhibits BTK activity, thereby preventing both B-cell activation and B-cell-mediated signaling. This leads to an inhibition of the growth of malignant B cells that overexpress BTK. BTK, a member of the src-related BTK/Tec family of cytoplasmic tyrosine kinases, is required for B cell receptor signaling, plays a key role in B-cell maturation, and is overexpressed in a number of B-cell malignancies. The expression of BTK in tumor cells is also associated with increased proliferation and survival.

Biomarker-Directed Therapies

Clinical Trials

View Clinical Trials for ibrutinib

Ibrutinib has been investigated in 121 clinical trials, of which 106 are open and 15 are closed. Of the trials investigating ibrutinib, 2 are early phase 1 (2 open), 29 are phase 1 (27 open), 28 are phase 1/phase 2 (23 open), 48 are phase 2 (41 open), 1 is phase 2/phase 3 (1 open), 12 are phase 3 (11 open), and 1 is phase 4 (1 open).

MS4A1 Expression, CCND1 Expression, and CD19 Expression are the most frequent biomarker inclusion criteria for ibrutinib clinical trials.

Mantle cell lymphoma, chronic lymphocytic leukemia, and diffuse large B-cell lymphoma are the most common diseases being investigated in ibrutinib clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Ibrutinib
Top Biomarker Inclusion Criteria for Closed Clinical Trials Investigating Ibrutinib
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating ibrutinib and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
pci-32765, Imbruvica, 1-[(3r)-3-[4-amino-3-(4-phenoxyphenyl)-1h-pyrazolo[3,4-d]pyrimidin-1-yl]piperidin-1-yl]prop-2-en-1-one, bruton's tyrosine kinase inhibitor pci-32765, btk inhibitor pci-32765, btk inhibitor pci-32765, ibrutinib, 2-propen-1-one, 1-((3r)-3-(4-amino-3-(4-phenoxyphenyl)-1h-pyrazolo(3,4-d)pyrimidin-1-yl)-1-piperidinyl)-, pci 32765, pci32765, ibrutinib (product), ibrutinib (substance), cra-032765, 2-propen-1-one, 1-((3r)-3-(4-amino-3-(4-phenoxyphenyl)-1h-pyrazolo(3,4-d)pyrimidin-1-yl)-1-piperidinyl)-, ibrutinib
Drug Categories [2]:
Tyrosine kinase inhibitors
Drug Target(s) [2]:
BTK
NCIT ID [1]:
C81934
SNOMED ID [1]:
R-FF6EA

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.